Ambrx hires Peter Kiener as Chief Scientific Officer

Brings expertise in development of next-generation biologic therapeutics to US firm

Ambrx, a clinical stage biopharmaceutical firm based in La Jolla, California, US, has appointed Peter Kiener as Chief Scientific Officer.

Kiener brings decades of expertise in the development of next-generation biologic therapeutics to the firm, including multi-specific, antibody based biologics from his former role as President, Chief Executive and Co-Founder of Zyngenia.

Kiener's knowledge is expected to help Ambrx further advance its pipeline of antibody drug conjugate (ADC) and bispecific antibody therapeutics.

Prior to Zyngenia, Kiener was Executive Vice President and Global Head of Biologics Research and Development at MedImmune, the biologics arm of AstraZeneca. He also held multiple positions at Bristol-Myers Squibb over an 18-year period, 10 years of which were spent working on biological therapeutics.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

A bullish time for biotech

Biotechnology has changed healthcare radically over the past decade and its impact on the pharmaceutical sector is growing. Susan Birks reports on the impact of the biotech boom
Finance

Chinese consortium to acquire US biotech Ambrx

Group comprises Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech
Research & Development

BMS partners Ambrx in up to US$112m ADC deal

To develop antibody drug candidates for cancer indications
Research & Development

Merck & Co collaborates with Ambrx

Will develop biologic drug conjugates using Ambrx protein technology
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Pharmaceutical

High-precision temperature control solutions for the pharmaceutical industry and biotechnology, available in the UK from Labtex

Huber offers a world-renowned range of temperature control systems and associated accessories for the Pharmaceutical Industry and Biotechnology
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Subscribe now